Immunotherapy in oncogene addicted non-small cell lung cancer

由 McLean, Luke, Leal, Jose Luis, Solomon, Benjamin J., John, Thomas
發表在 Transl Lung Cancer Res (2021)

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

由 Cameron, Laird B, Hitchen, Nadia, Jordan, Vanessa, Manser, Renée, Solomon, Benjamin J
發表在 Cochrane Database Syst Rev (2019)

Clinical Management of Adverse Events Associated with Lorlatinib

由 Bauer, Todd M., Felip, Enriqueta, Solomon, Benjamin J., Thurm, Holger, Peltz, Gerson, Chioda, Marc D., Shaw, Alice T.
發表在 Oncologist (2019)

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival

由 Freudenstein, Donald, Litchfield, Cassandra, Caramia, Franco, Wright, Gavin, Solomon, Benjamin J., Ball, David, Keam, Simon P., Neeson, Paul, Haupt, Ygal, Haupt, Sue
發表在 Cancers (Basel) (2020)

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

由 Solomon, Benjamin J., Desai, Jayesh, Rosenthal, Mark, McArthur, Grant A., Pattison, Scott T., Pattison, Stacey L., MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Scott, Andrew M.
發表在 PLoS One (2015)

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive...

由 Berge, Eamon M., Lu, Xian, Maxson, Delee, Barón, Anna E., Gadgeel, Shirish M., Solomon, Benjamin J., Doebele, Robert C., Varella-Garcia, Maria, Camidge, D. Ross
出版 2013

An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic

由 Degeling, Koen, Baxter, Nancy N., Emery, Jon, Jenkins, Mark A., Franchini, Fanny, Gibbs, Peter, Mann, G. Bruce, McArthur, Grant, Solomon, Benjamin J., IJzerman, Maarten J.
發表在 Asia Pac J Clin Oncol (2021)

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

由 Dagogo-Jack, Ibiayi, Gainor, Justin F., Porter, Rebecca L., Schultz, Katherine R., Solomon, Benjamin J., Stevens, Sara, Azzoli, Christopher G., Sequist, Lecia V., Lennes, Inga T., Shaw, Alice T.
發表在 J Thorac Oncol (2016)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

由 Nishio, Makoto, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Solomon, Benjamin J., Shaw, Alice T., Hashigaki, Satoshi, Ohki, Emiko, Usari, Tiziana, Paolini, Jolanda, Polli, Anna, Wilner, Keith D., Mok, Tony
發表在 Cancer Res Treat (2018)

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

由 Gainor, Justin F., Tan, Daniel S.W., De Pas, Tomasso, Solomon, Benjamin J., Ahmad, Aziah, Lazzari, Chiara, de Marinis, Filippo, Spitaleri, Gianluca, Schultz, Katherine, Friboulet, Luc, Yeap, Beow Y., Engleman, Jeffrey A., Shaw, Alice T.
發表在 Clin Cancer Res (2015)

Complex renal cysts associated with crizotinib treatment

由 Schnell, Patrick, Bartlett, Cynthia H, Solomon, Benjamin J, Tassell, Vanessa, Shaw, Alice T, de Pas, Tommaso, Lee, Soo-Hyun, Lee, Geon Kook, Tanaka, Kaoru, Tan, Weiwei, Tang, Yiyun, Wilner, Keith D, Safferman, Allan, Han, Ji-Youn
發表在 Cancer Med (2015)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

由 Shaw, Alice T., Felip, Enriqueta, Bauer, Todd M., Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F., Johnson, Melissa, Dietrich, Jorg, James, Leonard P., Clancy, Jill S., Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J.
發表在 Lancet Oncol (2017)

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

由 Costa, Daniel B., Shaw, Alice T., Ou, Sai-Hong I., Solomon, Benjamin J., Riely, Gregory J., Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S. Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D., Wiltshire, Robin, Camidge, D. Ross, Crinò, Lucio
發表在 J Clin Oncol (2015)

MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

由 Lennerz, Jochen K., Kwak, Eunice L., Ackerman, Allison, Michael, Michael, Fox, Stephen B., Bergethon, Kristin, Lauwers, Gregory Y., Christensen, James G., Wilner, Keith D., Haber, Daniel A., Salgia, Ravi, Bang, Yung-Jue, Clark, Jeffrey W., Solomon, Benjamin J., Iafrate, A. John
出版 2011

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

由 Katayama, Ryohei, Shaw, Alice T., Khan, Tahsin M., Mino-Kenudson, Mari, Solomon, Benjamin J., Halmos, Balazs, Jessop, Nicholas A., Wain, John C., Yeo, Alan Tien, Benes, Cyril, Drew, Lisa, Saeh, Jamal Carlos, Crosby, Katherine, Sequist, Lecia V., Iafrate, A. John, Engelman, Jeffrey A.
出版 2012

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-...

由 Blackhall, Fiona, Ross Camidge, D, Shaw, Alice T, Soria, Jean-Charles, Solomon, Benjamin J, Mok, Tony, Hirsh, Vera, Jänne, Pasi A, Shi, Yuankai, Yang, Pan-Chyr, Pas, Tommaso De, Hida, Toyoaki, Carpeño, Javier De Castro, Lanzalone, Silvana, Polli, Anna, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Kim, Dong-Wan
發表在 ESMO Open (2017)

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

由 Shaw, Alice T., Solomon, Benjamin J., Besse, Benjamin, Bauer, Todd M., Lin, Chia-Chi, Soo, Ross A., Riely, Gregory J., Ou, Sai-Hong Ignatius, Clancy, Jill S., Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D. Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M., Felip, Enriqueta, Martini, Jean-François
發表在 J Clin Oncol (2019)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updat...

由 Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S W, Felip, Enriqueta, Chow, Laura Q M, Camidge, D Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J, Solomon, Benjamin J, Wolf, Jürgen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro, Shaw, Alice T
發表在 Lancet Oncol (2016)

BM-32 CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

由 Shaw, Alice, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Ross Camidge, D., Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro, Kim, Dong-Wan
出版 2014

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

由 Giuffrida, Lauren, Sek, Kevin, Henderson, Melissa A., Lai, Junyun, Chen, Amanda X. Y., Meyran, Deborah, Todd, Kirsten L., Petley, Emma V., Mardiana, Sherly, Mølck, Christina, Stewart, Gregory D., Solomon, Benjamin J., Parish, Ian A., Neeson, Paul J., Harrison, Simon J., Kats, Lev M., House, Imran G., Darcy, Phillip K., Beavis, Paul A.
發表在 Nat Commun (2021)